These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 9513413)

  • 1. [Autoantibodies against GAD and GAD65].
    Tsujii S
    Nihon Rinsho; 1998 Jan; 56 Suppl 3():190-5. PubMed ID: 9513413
    [No Abstract]   [Full Text] [Related]  

  • 2. [Autoantibodies against GAD, GAD65 and IA-2].
    Tsujii S
    Nihon Rinsho; 2002 Aug; 60 Suppl 8():395-400. PubMed ID: 12355780
    [No Abstract]   [Full Text] [Related]  

  • 3. Humoral autoimmune responses to glutamic acid decarboxylase have similar target epitopes and subclass that show titer-dependent disease association.
    Piquer S; Belloni C; Lampasona V; Bazzigaluppi E; Vianello M; Giometto B; Bosi E; Bottazzo GF; Bonifacio E
    Clin Immunol; 2005 Oct; 117(1):31-5. PubMed ID: 16027042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti glutamate-decarboxylase antibodies: a liaison between localisation related epilepsy, stiff-person syndrome and type-1 diabetes mellitus.
    Szűcs A; Barcs G; Winkler G; Soós Z; Folyovich A; Kelemen A; Várallyay P; Kamondi A
    Ideggyogy Sz; 2014 Jul; 67(7-8):269-71. PubMed ID: 25509368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [GAD antibodies, GAD65 antibody].
    Yamanouchi T
    Nihon Rinsho; 1999 Dec; 57 Suppl():372-5. PubMed ID: 10778142
    [No Abstract]   [Full Text] [Related]  

  • 6. Glutamic acid decarboxylase autoantibodies in stiff-man syndrome and insulin-dependent diabetes mellitus exhibit similarities and differences in epitope recognition.
    Daw K; Ujihara N; Atkinson M; Powers AC
    J Immunol; 1996 Jan; 156(2):818-25. PubMed ID: 8543838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glutamic acid decarboxylase autoantibodies and neurological disorders.
    Vianello M; Tavolato B; Giometto B
    Neurol Sci; 2002 Oct; 23(4):145-51. PubMed ID: 12536283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Autoimmunity and glutamate decarboxylase antibodies in the pathogenesis of type I diabetes mellitus in experimental and clinical practice].
    Kucera P; Andĕl M; Treslová L
    Vnitr Lek; 1996 May; 42(5):359-67. PubMed ID: 8768297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of anti GAD65 autoantibodies with an ELISA before and after standardization with the new international reference serum.
    Pfützner A; Forst T; Ambrosch A; Schmitz H; Lichtwald K; Beyer J
    Exp Clin Endocrinol Diabetes; 1995; 103(2):123-5. PubMed ID: 7553076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection and immunochemical characterization of glutamic acid decarboxylase autoantibodies in patients with autoimmune diabetes mellitus.
    Villalba A; Iacono RF; Valdez SN; Poskus E
    Autoimmunity; 2008 Mar; 41(2):143-53. PubMed ID: 18324484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association.
    Saiz A; Blanco Y; Sabater L; González F; Bataller L; Casamitjana R; Ramió-Torrentà L; Graus F
    Brain; 2008 Oct; 131(Pt 10):2553-63. PubMed ID: 18687732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The $64000 question in diabetes continues.
    Atkinson MA
    Lancet; 2000 Jul; 356(9223):4-6. PubMed ID: 10892753
    [No Abstract]   [Full Text] [Related]  

  • 13. Autoimmunity to glutamic acid decarboxylase in the neurodegenerative disorder Batten disease.
    Ramirez-Montealegre D; Chattopadhyay S; Curran TM; Wasserfall C; Pritchard L; Schatz D; Petitto J; Hopkins D; She JX; Rothberg PG; Atkinson M; Pearce DA
    Neurology; 2005 Feb; 64(4):743-5. PubMed ID: 15728308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Predictive, diagnostic, and prognostic value of the anti-GAD antibody].
    Takahashi K; Satoh J
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():19-24. PubMed ID: 12386973
    [No Abstract]   [Full Text] [Related]  

  • 15. GAD65-Reactive T cells in a non-diabetic stiff-man syndrome patient.
    Schloot NC; Batstra MC; Duinkerken G; De Vries RR; Dyrberg T; Chaudhuri A; Behan PO; Roep BO
    J Autoimmun; 1999 Jun; 12(4):289-96. PubMed ID: 10330300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of hydroxyl radical modified GAD65: a potential autoantigen in type 1 diabetes.
    Khan MW; Sherwani S; Khan WA; Ali R
    Autoimmunity; 2009 Feb; 42(2):150-8. PubMed ID: 19085183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stiff-person syndrome associated with cerebellar ataxia and high glutamic acid decarboxylase antibody titer.
    Kono S; Miyajima H; Sugimoto M; Suzuki Y; Takahashi Y; Hishida A
    Intern Med; 2001 Sep; 40(9):968-71. PubMed ID: 11579968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Anti GAD (glutamic acid decarboxylase) antibody].
    Yamanouchi T
    Nihon Rinsho; 2005 Aug; 63 Suppl 8():555-7. PubMed ID: 16149576
    [No Abstract]   [Full Text] [Related]  

  • 19. GAD, diabetes, and Stiff-Man syndrome: some progress and more questions.
    Solimena M; Butler MH; De Camilli P
    J Endocrinol Invest; 1994; 17(7):509-20. PubMed ID: 7829825
    [No Abstract]   [Full Text] [Related]  

  • 20. Autoantibodies against glutamic acid decarboxylase 65 in Japanese patients with insulin-dependent diabetes mellitus (IDDM).
    Yano M; Moriuchi R; Kawasaki E; Watanabe M; Saito K; Takino H; Akazawa S; Miyamoto T; Nagataki S
    J Autoimmun; 1995 Feb; 8(1):83-96. PubMed ID: 7734039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.